Photocure fundamentale forhold (PHO)

[nordpolen]

Tenkte det samme som deg, at COV sin tech kan være relevant for PHO. Det er nok en god del utvikling som må gjøres, men de har en del fellesnevnere ved at de tolker visuelle data.

[solskimm]

@nordpolen

COV

*CONTX
(jeg sier det bare for at jeg har lett etter CONTEXTVISION så mange ganger, men bare husket den gamle tickeren COV)

[TekBot]

Photocure ASA - Initiation of a share buyback

Oslo, Norway, June 7, 2021

Photocure ASA (“Photocure” or the “Company”) has decided to initiate a buyback
…

Vis børsmeldingen

of up to 50,000 of its own shares for a total maximum amount of NOK 12,500,000.
The buyback program may be carried out in the period from this announcement and
until June 30, 2021.

The purpose of the program is to acquire shares that can be used as settlement
in the Company’s share-based incentive scheme. Any acquired shares may also be
used for subsequent reduction of the capital of the Company or to meet
obligations arising from debt financial instruments that are exchangeable into
equity instruments in compliance with the EU Market Abuse Regulation article 5,
and as approved by the general meeting of the Company.

The buybacks will be made in accordance with the authorisation granted to the
board of directors by the Company’s annual general meeting held on May 20, 2021.
According to the authorisation, up to 2,682,000 shares may be purchased at a
minimum of NOK 0.50 and a maximum of NOK 250 per share. The authorisation is
valid until the annual general meeting in 2022, however no later than June 30,
2022.

All acquisitions under the buyback program will be executed on Euronext Oslo
Børs. The execution of any repurchases will depend on market conditions, the
buyback programme may be discontinued at any time and the Company may resolve to
terminate the buyback programme before the threshold set out above is reached.

Photocure owns 21,010 own shares in the Company as of the date of this
announcement.

For further information, please contact:
Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This is information is made public by the Company pursuant to the EU Market
Abuse Regulation article 5, as supplemented by Commission Delegated Regulation
(EU) 2016/1052, and is subject to the disclosure requirements pursuant to
Section 5-12 the Norwegian Securities Trading Act.

Kilde

[TekBot]

Photocure ASA: Exercise of employee share options and share capital increase

Oslo, Norway, 7 June 2021: Participants in Photocure ASA’s (“Photocure” or the
“Company”) share option program have on 7 June 2021 exercised a total of 98,251
options distributed as follows:
…

Vis børsmeldingen

· 9,501 options exercised according to the option program for 2017 at a strike
price of NOK 38.06; and
· 88,750 options exercised according to the option program for 2019 at a
strike price of NOK 50.72

Each option gives a right to receive one share in the Company. The share options
are described in note 7 and 20 in Photocure’s annual financial statements for
2020.

Following the exercise, the Board of Directors, pursuant to authorisation
granted by the Company’s Annual General Meeting, has decided to increase the
Company’s share capital by NOK 49,125.50 by issuing 98,251 new shares, of par
value NOK 0.50. Subsequent to the transaction, Photocure’s share capital will be
NOK 13,459,160 divided into 26,918,320 shares, each share having a par value of
NOK 0.50 and carrying one vote in the Company’s general meeting.

The following options are exercised by primary insiders:

· Dan Schneider, CEO, has exercised 50,000 options
· Erik Dahl, CFO, has exercised 10,000 options
· Grete Hogstad, VP Global Strategic Marketing & Business Development, has
exercised 6,250 options
· Kari Myren, VP Global Medical Affairs and Clinical Development, has
exercised 6,250 options

Primary insider notifications pursuant to the market abuse regulation article 19
are attached.

The primary insiders mentioned above have transferred their rights to receive
shares resulting from the exercise of options to a third party. Following a sale
of shares, the primary insiders will receive the net proceeds after deduction of
the strike price and accrued tax. The primary insiders will use the full net
proceeds to purchase shares in Photocure. The sales amount and the number of
shares purchased will be finally determined on the basis of the price
subsequently obtained by the third party in the market. The results of the sales
process will be announced in a separate stock exchange notice when known.

For further information, please contact:
Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.

Kilde

[TekBot]

Photocure ASA: Exercise of employee share options

Oslo, Norway, 8 June 2021: Reference is made to the stock exchange release by
Photocure ASA (“Photocure” or the “Company”) published on 7 June 2021 regarding
exercise of share options.
…

Vis børsmeldingen

The price for option shares sold by primary insiders have been determined at a
price of NOK 142.1646 per share.

The primary insiders having exercised options have used the net proceeds from
the sale of option shares to purchase shares in Photocure at a price per share
of NOK 142.1646 as follows:

· Dan Schneider, CEO, has purchased 18,921 shares
· Erik Dahl, CFO, has purchased 3405 shares
· Grete Hogstad, VP Global Strategic Marketing & Business Development, has
purchased 1971 shares
· Kari Myren, VP Global Medical Affairs and Clinical Development, has
purchased 1971 shares

The shares are purchased at the stated price from Photocure’s holding of own
shares. Following the transaction Photocure will hold 21,010 own shares.

Primary insider notifications pursuant to the market abuse regulation article 19
are attached.

For further information, please contact:
Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.

Kilde

[TekBot]

Photocure ASA: Acquisition of own shares under the share buy-back program for incentive scheme

Oslo, Norway, 8 June 2020: Reference is made to the stock exchange release by
Photocure ASA (“Photocure” or the “Company”) published on 7 June 2021 regarding
initiation of a share buyback program.
…

Vis børsmeldingen

The Company has completed its share buyback program. The Company has acquired a
total of 26,268 own shares at a price per share of NOK 142,1646. A report of all
the transactions relating to the buy-back programme, in a detailed form and in
an aggregated form is attached.

The shares acquired is used for the Company’s incentive scheme and sold to
employees.

After the acquisition and sale to employees, Photocure owns 21,010 own shares in
the Company.

For further information, please contact:
Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This is information is made public by the Company pursuant to the EU Market
Abuse Regulation article 5, as supplemented by Commission Delegated Regulation
(EU) 2016/1052, and is subject to the disclosure requirements pursuant to
Section 5-12 the Norwegian Securities Trading Act.

Kilde

[TekBot]

Photocure ASA: Exercise of employee share options - Correction

Oslo, Norway, 9 June 2021: Reference is made to the stock exchange release by
Photocure ASA (“Photocure” or the “Company”) published on 7 June 2021 regarding
exercise of share options.
…

Vis børsmeldingen

The price for option shares sold by primary insiders have been determined at a
price of NOK 142.1646 per share.

The primary insiders having exercised options have used the net proceeds from
the sale of option shares to purchase shares in Photocure at a price per share
of NOK 142.1646 as follows:

· Dan Schneider, CEO, has purchased 18,921 shares
· Erik Dahl, CFO, has purchased 3,405 shares
· Grete Hogstad, VP Global Strategic Marketing & Business Development, has
purchased 1,971 shares
· Kari Myren, VP Global Medical Affairs and Clinical Development, has
purchased 1,971 shares

The shares are purchased at the stated price from Photocure’s holding of own
shares. Following the transaction Photocure will hold 21,010 own shares.

Primary insider notifications pursuant to the market abuse regulation article 19
are attached*.

*New attachment

For further information, please contact:
Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.

Kilde

[ufo]

https://soundcloud.com/user-972208711/episode-181
Handler om PHO

[Bingo123]

Noe nytt og spennende som kom frem?

[Fartin]

Denne podcasten er noe av det mest oppløftende jeg har hørt i radforsk sammenheng. De sier jo at det går mot soc for Blue light. Hvordan skal man regne på caset da? Ett jevnt vekst case pho. Var med fra 27-98. Etter en pause er jeg tilbake. Det blir for vondt å se den vokse jevnt uten å være med.

[jadaok]

Enig med deg. Daniel Schneider virker å være helt gull. Skikkelig businessmann med klare mål. Samtidig framstår han åpen og ærlig. Snøballen har virkelig begynt å rulle for å nå målet om standard of care!

[TekBot]

Photocure ASA: Share capital increase registered

Oslo, Norway, 14 June 2021: Reference is made to the stock exchange release by
Photocure ASA (“Photocure” or the “Company”) published on 7 June 2021 regarding
a share capital increase following the exercise of share options.
…

Vis børsmeldingen

The issuance of 98,251 new shares has been registered with the Norwegian
Register of Business Enterprises. Following registration, the share capital of
Photocure is NOK 13,459,160 divided into 26,918,320 shares, each share having a
par value of NOK 0.50 and carrying one vote in the Company’s general meeting.

For further information, please contact:
Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to sections
5-12 of the Norwegian Securities Trading Act.

Kilde

[Quadruple]

New study finds that use of Blue Light Cystoscopy after BCG induction increases the detection of BCG-refractory Bladder Cancer tumors

https://photocure.com/news/new-study-finds-that-use-of-blue-light-cystoscopy-after-bcg-induction-increases-the-detection-of-bcg-refractory-bladder-cancer-tumors/

[Fartin]

Hvorfor børsmelder de ikke??

[Quadruple]

Børsmelder hva?

[Fartin]

Kan ikke se at den studien over ble børsmeldt?

[HeldigFyr]

	Photocure: Asieris Announces First Patient Administration in Europe within the Phase III Clinical Trial for APL-1702 (Cevira)
	Oslo, Norway, 22 June, 2021: Photocure ASA (OSE:PHO) today announces that its partner Asieris Pharmaceuticals (Asieris) has administered the first European patient in its phase III clinical trial for APL-1702 (Cevira®).

Photocure: Asieris Announces First Patient Administration in Europe within...

[Fartin]

Hvor mye gjenstår av milestones? Denne nyheten gir vel en del milestones.

[Tekspert]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @Rodjer (187 likes)

@Rodjer

Ny klinikk oppført på Cysview.

2. @Snoeffelen (174 likes)

@Snoeffelen

Min ståsted er at de dataene vi allerede har på Cevira er meget sterke, og i artikkelen skrevet av Jacob Plieth i 2013 “Photocure shops for partners as Cevira data weaken”, er vel defensiv, og egentlig litt “weak”.

3. @Savepig (66 likes)

@Savepig

ABG fornyer BUY på Photocure, kursmål 172

Resten av topp 10:

4. @rosk82 (61 likes)

5. @CanonBoy (43 likes)

6. @tooeasy891 (33 likes)

7. @HeldigFyr (33 likes)

8. @myk (30 likes)

9. @OYV (25 likes)

10. @togulle (24 likes)

Gratulerer!

[TekBot]

Photocure ASA - Notice of an extraordinary general meeting 28 July 2021

Oslo, Norway, 7 July 2021: Photocure ASA (OSE: PHO), calls for an extraordinary
general meeting of Photocure to be held in Advokatfirmaet Selmer AS’ premises in
Tjuvholmen allé 1, 0252 Oslo on 28 July 2021 at 17:00 hours (CEST).
…

Vis børsmeldingen

The notice convening the extraordinary general meeting, including the agenda and
the nomination committee’s proposal to the matter to be dealt with, is enclosed
with this notification and will be sent to all shareholders with known
addresses.

Relevant documents referred to in the notice are made available on
www.photocure.com.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000
mail: ed@photocure.com

About Photocure ASA Photocure:
The Bladder Cancer Company delivers transformative solutions to improve the
lives of bladder cancer patients. Our unique technology, which makes cancer
cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde